Nucleic-acid- and cell-based therapeutics - Pharmaceutical Biotechnology: Concepts and Aapplications - page 464

Yechoor, V and Chan, L. 2005. Gene therapy progress and prospects: gene therapy for diabetes mellitus. Gene
Therapy 12 (2), 101-107.
Young, L.S., Searle, P.F., Onion, D., and Mautner, V. 2006. Viral gene therapy strategies: from basic science to
clinical application. Journal of Pathology 208 (2), 299-318.
Antisense technology
Aboul-Fadt, T. 2005. Antisense oligonucleotides: the state of the art. Current Medicinal Chemistry 12 (19),
2193-2214.
Adah, S.A., Bayly, S.F., Cramer, H., Silverman, R.H., and Torrence, P.F. 2001. Chemistry and biochemistry of
2´, 5´-oligoadenylate-based antisense strategy. Current Medicinal Chemistry 8 (10), 1189-1212.
Akhtar, S., Hughes, M.D., Khan, A., Bibby, M., Hussain, M., Nawaz, Q., Double, J., and Sayyed, P. 2000. The
delivery of antisense therapeutics. Advanced Drug Delivery Reviews 44 (1), 3-21.
Galderisi, U., Cipollaro, M., and Cascino, A. 2001. Antisense oligonucleotides as drugs for HIV treatment. Expert
Opinion on Therapeutic Patents 11 (10), 1605-1611.
Hughes, M.D., Hussain, M., Nawaz, Q., Sayyed, P., and Akhtar, S. 2001. The cellular delivery of antisense
oligonucleotides and ribozymes. Drug Discovery Today 6 (6), 303-315.
Jason, T.L.H., Koropatnick, J., and Berg, R.W. 2004. Toxicology of antisense therapeutics. Toxicology and Applied
Pharmacology 201 (1), 66 -83.
Lebedeva, I. and Stein, C. 2001. Antisense oligonucleotides: promise and reality. A n n u a l Re vie w o f Ph ar m a colog y
and Toxicology 41 , 403-419.
Rubenstein, M., Tsui, P., and Guinan, P. 2004. A review of antisense oligonucleotides in the treatment of human
disease. Drugs of the Future 29 (9), 893-909.
Stein, C.A., Benimetskaya, L., and Mani, S. 2005. Antisense strategies for oncogene inactivation. Seminars in
Oncology 32 (6), 563-572.
Vidal L., Blagden, S., Attard, G., and de Bono, J. 2005. Making sense of antisense. European Journal of Cancer
41 (18), 2812-2818.
RNA interference
Amarzguioui, M., Rossi, J.J., and Kim, D. 2005. Approaches for chemically synthesized siRNA and vector-
mediated RNAi. FEBS Letters 579 (26), 5974-5981.
Bagasra, O. 2005. RNAi as an antiviral therapy. Expert Opinion on Biological Therapy 5 (11), 1463-1474.
Campbell, T. and Choy, F. 2005. RNA interference: past, present and future. Current Issues in Molecular
Biology 7 , 1-6.
Caplen, N. 2003. RNAi as a gene therapy approach. Expert Opinion on Biological Therapy 3 (4), 575-568.
Chowdhury, D. and Novina, C. 2005. RNAi and RNA-based regulation of immune system function. Advances in
Immunology 88 (88), 267-292.
Pai, S.I., Lin, Y.Y., Macaes, B., Meneshian, A., Hung, C.F., and Wu, T.C. 2006. Prospect of RNA interference
therapy for cancer. Gene Therapy 13 (6), 464-477.
Uprichard, S. 2005. The therapeutic potential of RNA interference. FEBS Letters 579 (26), 5996-6007.
Ribozymes
Alvarez-Salas, L.M., Benitez-Hess, M.L., and DiPaolo, J.A. 2003. Advances in the development of ribozymes
and antisense oligodeoxynucleotides as antiviral agents for human papillomaviruses. Antiviral Therapy 8 (4),
265-278.